MSCs Therapy for Cerebral Palsy

Stem Cell Transplant Complications Clinical Trial

Official title:

Bone Marrow Stem Cells Transplantation for the Treatment of Cerebral Palsy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04653077
• Other study ID #: cerebral palsy
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2, 2020
• Est. completion date: December 1, 2022

Study information

• Verified date: November 2020
• Source: Aljazeera Hospital
• Contact: amr khalil
• Phone: 01223292124
• Email: amrkhalil273[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cerebral palsy (CP) is the most common physical disability in childhood. CP comprises a heterogeneous group of disorders that are the result of a non-progressive disruption or injury that occurred during fetal brain development or within the first two years of life.

Description:

This disruption can result in spasticity, dystonia, muscle contractures, weakness and difficulty in coordination that ultimately affects the ability to control movements. Resultant activity limitations may affect gross motor movements, fine motor movements, speech and communication, as well as eating and drinking.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 1, 2022
• Est. primary completion date: October 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 12 Years

Eligibility

Inclusion Criteria:

• • Must be more than 2 year of age and less than 12 years of age at the time of screening for inclusion in the study.
• Clinical evidence of a non-progressive motor disability due to brain dysfunction.

Exclusion Criteria:

• • Intractable seizures
• Traumatic brain injury
• Genetic disorder
• Current Infection
• Renal insufficiency
• Hepatic disease
• HIV+ (as demonstrated by positive blood test)
• Immunosuppression

Related Conditions & MeSH terms

• Cerebral Palsy
• Stem Cell Transplant Complications

Intervention

Other:
• stem cells
Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.

Locations

Country	Name	City	State
Egypt	Aljazeera( Al Gazeera) hospital	Giza

Sponsors (2)

Lead Sponsor	Collaborator
Aljazeera Hospital	AMR KHALIL ORTHOPEDIC SURGERY CENTER

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Motor Performance.	the number of patients who will have changes in motor performance	6 months